Retinal Vein Occlusion - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 76
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RF34FE1F9C4EN
Leaflet:

Download PDF Leaflet

Retinal Vein Occlusion - Pipeline Review, H2 2016
Retinal Vein Occlusion - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2016, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 7 and 1 respectively.Retinal Vein Occlusion.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Retinal Vein Occlusion Overview
Therapeutics Development
Pipeline Products for Retinal Vein Occlusion - Overview
Retinal Vein Occlusion - Therapeutics under Development by Companies
Retinal Vein Occlusion - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Retinal Vein Occlusion - Products under Development by Companies
Retinal Vein Occlusion - Companies Involved in Therapeutics Development
Aerpio Therapeutics, Inc.
Clearside BioMedical, Inc.
Formycon AG
Kala Pharmaceuticals, Inc.
Mabion SA
NicOx S.A.
Ohr Pharmaceutical Inc.
Precision Ocular Ltd
ThromboGenics NV
Retinal Vein Occlusion - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aflibercept + triamcinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-9778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HO-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LKA-651 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loteprednol etabonate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-434 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ocriplasmin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Ophthalmology and Orphan Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squalamine lactate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinal Vein Occlusion - Dormant Projects
Retinal Vein Occlusion - Discontinued Products
Retinal Vein Occlusion - Product Development Milestones
Featured News & Press Releases
Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion
Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema
Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Retinal Vein Occlusion, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H2 2016
Retinal Vein Occlusion - Pipeline by Clearside BioMedical, Inc., H2 2016
Retinal Vein Occlusion - Pipeline by Formycon AG, H2 2016
Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2016
Retinal Vein Occlusion - Pipeline by NicOx S.A., H2 2016
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H2 2016
Retinal Vein Occlusion - Pipeline by Precision Ocular Ltd, H2 2016
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Retinal Vein Occlusion - Dormant Projects, H2 2016
Retinal Vein Occlusion - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Retinal Vein Occlusion, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Retinal Vein Occlusion - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: